Major trial challenges how doctors decide who really needs statins

Major trial challenges how doctors decide who really needs statins

- Date:

- November 6, 2026

- Source:

- European Society of Cardiology

- Summary:

- A study of nearly 5,800 adults found that heart scans measuring calcium buildup in the arteries led to the same observed rate of major cardiovascular events as traditional risk assessments, despite recommending statins to far fewer patients. Surprisingly, patients advised to take statins based on their scans were nearly three times as likely to stick with their medication, raising intriguing questions about how doctors should identify and treat heart disease risk.

- Share:

A major clinical trial has raised new questions about how doctors decide who should take statins to prevent heart attacks and strokes. Researchers found that using heart scans to guide treatment decisions produced the same observed rate of major cardiovascular events as traditional risk assessments, even though the scans led to far fewer recommendations to begin taking statins.

The findings, presented during a Hot Line session at ESC Congress 2026, also revealed a striking difference in how consistently patients took their medication. Those advised to use statins based on calcium buildup in their coronary arteries were substantially more likely to follow their treatment recommendations.

Although the results suggest that heart scans could help doctors make more targeted treatment decisions, the trial did not establish that the scan approach was as effective as conventional risk assessment. Researchers say additional studies are needed to determine whether it offers a better strategy for preventing cardiovascular disease.

Why Predicting Heart Disease Risk Remains a Challenge

Cardiovascular disease remains the world's leading cause of illness and death. Much of this burden comes from atherosclerotic cardiovascular disease (ASCVD), which develops when fatty deposits known as plaque accumulate inside arteries, restricting blood flow and increasing the risk of heart attacks and strokes. Coronary artery disease and ischemic stroke are two major forms of this condition.

Several common factors increase the likelihood of developing ASCVD, including smoking, diabetes, high blood pressure, and elevated cholesterol. Doctors use these factors to estimate a person's cardiovascular risk and determine whether preventive medications are appropriate.

Statins are among the most widely used treatments for lowering that risk. These medications reduce cholesterol levels, particularly low-density lipoprotein cholesterol, often called LDL or bad cholesterol. They also help lower the likelihood of serious cardiovascular complications.

However, identifying which patients stand to benefit from statins remains a significant challenge. Some people who eventually experience a heart attack do not appear to be at particularly high risk under conventional screening methods.

"For far too many patients, the first symptom of ASCVD is a heart attack," said Doctor Joseph B Muhlestein from the Intermountain Medical Center, Murray, USA, the Principal Investigator of the CorCal Outcomes trial. "Statins have been shown to be highly effective in the prevention of ASCVD; however, there is a major gap in risk assessment, statin initiation, and statin persistence."

According to Muhlestein, many people who suffer their first heart attack, particularly younger adults, would not previously have been classified as having enough cardiovascular risk to justify statin treatment. This limitation has prompted researchers to investigate whether directly examining the arteries might provide more useful information.

Can Heart Calcium Scans Improve Statin Decisions?

The CorCal Outcomes trial investigated two different approaches for determining which patients should be advised to begin statin therapy before experiencing a cardiovascular event.

The first relied on the pooled cohort equations (PCE), a commonly used risk assessment tool that estimates cardiovascular risk using traditional factors such as age, cholesterol levels, blood pressure, and smoking status.

The second approach measured coronary artery calcium (CAC), which provides a more direct indication of plaque buildup in the arteries supplying the heart.

This measurement uses a computed tomography (CT) scan to detect calcium deposits in the coronary arteries. Calcium can accumulate within atherosclerotic plaque, making it a useful marker of underlying coronary artery disease, even in people who have not developed symptoms.

Unlike traditional risk calculators, which estimate the likelihood of future cardiovascular problems based on personal characteristics and health measurements, calcium scans provide evidence of disease already present in the coronary arteries.

Researchers wanted to determine whether using this information to guide statin recommendations could improve cardiovascular outcomes.

Nearly 5,800 Patients Put Both Methods to the Test

The trial enrolled 5,772 patients from the Canyons and Desert regions of Intermountain Health Care in the United States. Participants had no known history of ASCVD or diabetes and had not previously received statin therapy.

Their average age was 64, and women accounted for 51% of the study population.

Eligible participants were randomly assigned (1:1) to one of two groups. One group received statin treatment guidance based on traditional cardiovascular risk scores, while the other received recommendations based on coronary calcium scan results.

Both patients and their physicians were informed of the treatment recommendations generated by the study protocol. However, the final decision about whether to start taking statins remained with the patients and their doctors.

The researchers then tracked major cardiovascular events (MACE; all-cause mortality, myocardial infarction, stroke, and arterial revascularization).

This combined outcome included death from any cause, heart attacks, strokes, and procedures to restore blood flow through narrowed or blocked arteries.

Heart Scans Led to Far Fewer Statin Recommendations

After an average follow-up of 4.2 years, researchers found that major cardiovascular events occurred at exactly the same observed rate in both groups.

A total of 2.7% of patients in each group experienced one of the events included in the study's primary outcome. The estimated relative risk over time was also nearly identical (hazard ratio 0.99; 95% confidence interval 0.71 to 1.38; p=0.045 for noninferiority).

However, this similarity did not establish that the two strategies were equally effective. The study failed to meet its predetermined statistical requirement for demonstrating that the calcium scan approach was not meaningfully worse than conventional risk assessment.

A notable difference emerged in how frequently patients were advised to begin taking statins.

Participants evaluated using traditional risk scores received recommendations to start statin therapy more than three times as often as those whose decisions were guided by coronary calcium measurements.

Despite this substantial difference in treatment recommendations, both groups experienced the same observed rate of major cardiovascular events during the follow-up period.

A Surprising Difference in Statin Adherence

Perhaps the most intriguing finding involved whether patients actually followed their prescribed treatment.

Among those advised to take statins, patients whose recommendations were based on calcium scans were much more likely to adhere to their medication regimen than those assessed using traditional cardiovascular risk factors.

The difference was substantial (62% vs. 23%).

In other words, patients recommended statins based on visible evidence of calcium buildup in their arteries were approximately 2.7 times as likely to follow their medication regimen.

One possible explanation is that seeing evidence of disease in their own arteries makes patients more motivated to take preventive medication. However, the trial did not establish why adherence differed so dramatically between the groups.

The findings raise the possibility that coronary calcium scans could influence not only which patients receive statin recommendations, but also whether those patients consistently take the medications.

What the Findings Mean for Heart Disease Prevention

Despite these potentially important differences, the researchers emphasized that the study could not establish whether calcium scan-guided treatment provides cardiovascular protection comparable to traditional risk assessment.

One important limitation was that fewer participants experienced major cardiovascular events than the investigators had anticipated. With fewer events to analyze, the trial had less statistical power to determine whether a meaningful difference existed between the two approaches.

"The power of the study to detect a difference was reduced by the lower-than-expected event rates and we did not demonstrate noninferiority between the groups," said Doctor Muhlestein, who concluded: "The study did provide important hypothesis-generating insights into the efficiency of statin initiation and adherence when decisions are based on CAC scoring. Taken together, our data could be used to plan an additional well-powered randomized trial comparing CAC with current risk factor-based algorithms."

The findings may help researchers design future trials capable of determining whether coronary calcium scans can improve the efficiency of statin prescribing without compromising cardiovascular protection.

Current European recommendations already recognize a potential role for these measurements. The 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidemias recommends considering increased coronary calcium scores, when available, as an additional factor in cardiovascular risk assessment.

This guidance applies particularly to people at moderate cardiovascular risk or those whose estimated risk falls near the threshold at which preventive medication would normally be recommended.

For these individuals, evidence of calcium buildup may help doctors make more informed decisions when the need for statin therapy is uncertain.

The CorCal Outcomes findings add to the discussion by suggesting that heart scans may also influence how faithfully patients follow treatment. Whether that advantage translates into better long-term cardiovascular outcomes remains an important question for future research.

Story Source:

Materials provided by European Society of Cardiology. Note: Content may be edited for style and length.

Cite This Page: